Table 3.
Cox regression analysis of progression‐free survival and overall survival
| Progression‐free survival | Overall survival | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
| HR | 95% CI | P‐value | HR | 95%CI | P‐value | HR | 95% CI | P‐value | HR | 95% CI | P‐value | |
| Age ≥75 vs. <75 | 0.91 | 0.59, 1.39 | 0.647 | 1.29 | 0.81, 2.05 | 0.284 | ||||||
| Sex male vs. female | 0.62 | 0.45, 0.85 | 0.004 | 0.89 | 0.57, 1.39 | 0.608 | 0.76 | 0.52, 1.10 | 0.146 | |||
| PS 0,1 vs. 2–4 | 0.41 | 0.28, 0.60 | <0.001 | 0.45 | 0.30, 0.67 | <0.001 | 0.26 | 0.17, 0.38 | <0.001 | 0.26 | 0.18, 0.40 | <0.001 |
| Smoking status never vs. current/former | 1.77 | 1.24, 2.51 | 0.002 | 1.48 | 0.92, 2.38 | 0.109 | 1.22 | 0.81, 1.83 | 0.336 | |||
| Histology sq vs. nonsq | 1.06 | 0.75, 1.51 | 0.735 | 1.22 | 0.81, 1.84 | 0.351 | ||||||
| EGFR/ALK positive vs. negative | 2.10 | 1.40, 3.14 | <0.001 | 1.61 | 0.99, 2.61 | 0.055 | 1.41 | 0.90, 2.22 | 0.138 | |||
| PD‐L1 positive vs. negative | 0.76 | 0.49, 1.17 | 0.212 | 1.22 | 0.67, 2.20 | 0.517 | ||||||
| Line of therapy second/third vs. fourth | 0.52 | 0.37, 0.74 | <0.001 | 0.84 | 0.53, 1.31 | 0.437 | 0.76 | 0.51, 1,14 | 0.185 | |||
| Active BM vs. nonactive BM | 2.51 | 1.61, 3.91 | <0.001 | 1.77 | 1.09, 2.86 | 0.022 | 2.25 | 1.34, 3.68 | 0.001 | 1.87 | 1.13, 3.11 | <0.001 |
| Steroid treatment (≥10 mg of PSL) Yes vs. No | 3.63 | 1.48, 8.91 | 0.005 | 4.06 | 1.61, 10.23 | 0.003 | 2.97 | 1.09, 8.13 | 0.034 | 2.96 | 1.06, 8.25 | <0.001 |
ALK, anaplastic lymphoma kinase rearrangement; CI, confidence intervals; EGFR, epidermal growth factor receptor; HR, hazard ratio; PD‐L1, programmed cell death‐ligand 1; PSL, prednisolone; squamous, squamous cell carcinoma; nonsq, nonsquamous.